Get the Stockscreener App
7.24
5.85%
-0.45
After Hours:
7.25
0.010
+0.14%
Recursion Pharmaceuticals Inc Stock (RXRX) Forecast
The Recursion Pharmaceuticals Inc (RXRX) stock price forecast for the next 30 days is generally negative, with an average analyst price target of $5.8411, representing a -19.32% decrease from the current price of $7.24. The highest analyst price target is $5.6019, and the lowest is $6.0803.
Disclaimer: The information on this page is not intended to be financial advice. It is for general information only and should not be used to make any investment decisions. Please consult with a professional financial advisor before making any investment decisions.
12-Month RXRX Price Target
Average 2.8214
(-61.03% Downside)
Is Recursion Pharmaceuticals Inc (RXRX) A Buy Now?
Oscillators
| Name | Value | Action |
|---|---|---|
| RSI(14) | 51.54 | Neutral |
| STOCH(9,6) | 49.87 | Neutral |
| STOCHRSI(14) | 61.75 | Neutral |
| MACD(12,26) | 0.1006 | Buy |
| ADX(14) | 24.85 | Neutral |
| William %R | -49.51 | Neutral |
| CCI(14) | 60.32 | Neutral |
Buy: 1
Sell: 0
Neutral: 6
Summary: Neutral
Moving Averages
| Period | Simple | Exponential |
|---|---|---|
| MA10 |
7.231
Buy
|
7.239
Buy
|
| MA20 |
7.139
Buy
|
7.1453
Buy
|
| MA50 |
6.9463
Buy
|
7.0248
Buy
|
| MA100 |
6.8022
Buy
|
7.0593
Buy
|
| MA200 |
7.4243
Sell
|
7.4059
Sell
|
Buy: 8
Sell: 2
Neutral: 0
Summary: Buy
According to our latest analysis, RXRX could be considered a Strong Buy, with 17 technical analysis indicators signaling 9 Buy signals, 2 signaling Sell signals and 6 Neutral signals. This might be a good time to open fresh positions on RXRX, as trading bullish markets is always a lot easier
- RSI (Relative Strength Index): The RSI(14) value of 51.54 indicates that RXRX is neither overbought nor oversold. It suggests a neutral sentiment in the short term.
- STOCH (Stochastic Oscillator): The STOCH value of 49.87 indicates that RXRX is neither overbought nor oversold. It indicates a balanced market sentiment without any extreme buying or selling pressure.
- STOCHRSI (Stochastic Relative Strength Index): The STOCHRSI value of 61.75 indicates that RXRX is neither overbought nor oversold. It indicates a balanced market sentiment without any extreme buying or selling pressure.
- ADX (Average Directional Index): The ADX value of The ADX value of 24.85 suggests that there may be some movement in price, but it lacks strength or conviction.
- CCI (Commodity Channel Index): A CCI(14) value of A CCI(14) value of 60.32 indicates that RXRX is still overbought but not to an extreme extent.
Long-term RXRX price forecast for 2025, 2030, 2035, 2040, 2045 and 2050
Based on our analysis about Recursion Pharmaceuticals Inc financial reports and earnings history, Recursion Pharmaceuticals Inc (RXRX) stock could reach $8.5765 by 2030, $57.31 by 2040 and $101.66 by 2050. See the projected annual prices until 2050 of the Recursion Pharmaceuticals Inc stock below:
- Recursion Pharmaceuticals Inc (RXRX) is expected to reach an average price of $31.14 in 2035, with a high prediction of $31.52 and a low estimate of $31.60. This indicates an $330.15% rise from the last recorded price of $7.24.
- Recursion Pharmaceuticals Inc (RXRX) stock is projected to chart a bullish course in 2040, with an average price target of $62.31, representing an $760.64% surge from its current level. The forecast ranges from a conservative $18.76 to a sky-high $57.31.
- Our analysts predict Recursion Pharmaceuticals Inc (RXRX) to jump 665.63% by 2045, soaring from $55.56 to an average price of $55.43, potentially reaching $54.70. While $55.56 is the low estimate, the potential upside is significant.
- Recursion Pharmaceuticals Inc (RXRX) stock is expected to climb by 2050, reaching an average of $100.55, a $1,289% jump from its current level. However, a wide range of estimates exists, with high and low targets of $101.66 and $101.47, respectively, highlighting the market's uncertainty.
Recursion Pharmaceuticals Inc Stock (RXRX) Year by Year Forecast
Recursion Pharmaceuticals Inc Stock (RXRX) Price Forecast for 2025
Recursion Pharmaceuticals Inc Stock (RXRX) is expected to reach an average price of $2.8214 in 2025, with a high prediction of $5.6019 and a low estimate of $0.0409. This indicates an -61.03% fall from the last recorded price of $7.24.
| Month | Average | Low | High | Change from today's price |
|---|---|---|---|---|
| March, 2025 | $6.2277 | $6.0803 | $5.6019 | -13.98% |
| April, 2025 | $3.7468 | $5.261 | $5.3935 | -48.25% |
| May, 2025 | $2.1901 | $2.9001 | $2.3343 | -69.75% |
| June, 2025 | $1.0234 | $2.7984 | $2.5176 | -85.86% |
| July, 2025 | $0.4325 | $0.6325 | $2.235 | -94.03% |
| August, 2025 | $0.1942 | $0.0659 | $3.6259 | -97.32% |
| September, 2025 | $0.8609 | $0.0409 | $1.5509 | -88.11% |
| October, 2025 | $0.6982 | $0.2601 | $3.2777 | -90.36% |
| November, 2025 | $1.3114 | $1.0798 | $0.494 | -81.89% |
| December, 2025 | $0.8205 | $1.2205 | $1.7131 | -88.67% |
Recursion Pharmaceuticals Inc Stock (RXRX) Price Forecast for 2026
The predicted value for Recursion Pharmaceuticals Inc (RXRX) in 2026 is set at an average of $4.484. Estimates vary from a peak of $8.8457 to a trough of $0.1222, indicating an -38.07% surge from the present price of $7.24.
| Month | Average | Low | High | Change from today's price |
|---|---|---|---|---|
| January, 2026 | $1.0638 | $1.338 | $0.8522 | -85.31% |
| February, 2026 | $0.5571 | $1.3371 | $1.0455 | -92.31% |
| March, 2026 | $2.1504 | $2.0587 | $1.8604 | -70.30% |
| April, 2026 | $3.3895 | $2.4062 | $3.2595 | -53.18% |
| May, 2026 | $0.4372 | $0.1222 | $2.5803 | -93.96% |
| June, 2026 | $0.756 | $0.1686 | $2.2748 | -89.56% |
| July, 2026 | $5.2749 | $0.9019 | $8.8457 | -27.14% |
| August, 2026 | $0.9516 | $0.7916 | $6.559 | -86.86% |
| September, 2026 | $1.2125 | $0.5183 | $2.3158 | -83.25% |
| October, 2026 | $0.7608 | $0.2908 | $1.5467 | -89.49% |
| November, 2026 | $1.0141 | $1.2716 | $1.5983 | -85.99% |
| December, 2026 | $0.7368 | $0.1532 | $1.0926 | -89.82% |
Recursion Pharmaceuticals Inc Stock (RXRX) Price Forecast for 2027
For 2027, Stockscan's Analyst expects the average price target for Recursion Pharmaceuticals Inc (RXRX) is $6.0318, with a high forecast of $11.66 and a low forecast of $0.401. This indicates an -16.69% decrease from the last price of $7.24.
| Month | Average | Low | High | Change from today's price |
|---|---|---|---|---|
| January, 2027 | $3.4235 | $0.401 | $4.7335 | -52.71% |
| February, 2027 | $3.5603 | $2.8727 | $7.8519 | -50.83% |
| March, 2027 | $7.4211 | $2.6178 | $9.3761 | +2.50% |
| April, 2027 | $5.4879 | $4.4279 | $9.8453 | -24.20% |
| May, 2027 | $2.8946 | $2.7996 | $6.667 | -60.02% |
| June, 2027 | $5.79 | $1.6738 | $3.4513 | -20.03% |
| July, 2027 | $0.8166 | $3.7666 | $5.4216 | -88.72% |
| August, 2027 | $4.3731 | $1.7982 | $1.7502 | -39.60% |
| September, 2027 | $7.6613 | $6.6248 | $7.2613 | +5.82% |
| October, 2027 | $7.5079 | $8.203 | $6.6779 | +3.70% |
| November, 2027 | $7.8244 | $7.8145 | $6.9122 | +8.07% |
| December, 2027 | $14.19 | $9.3161 | $11.66 | +96.03% |
Recursion Pharmaceuticals Inc Stock (RXRX) Price Forecast for 2028
In 2028, Recursion Pharmaceuticals Inc (RXRX) is projected to reach an average price of $13.60, with a high projection of $17.29 and a low estimate of $9.9147. This indicates an +87.90% rise from the last price of $7.24.
| Month | Average | Low | High | Change from today's price |
|---|---|---|---|---|
| January, 2028 | $13.02 | $13.94 | $13.37 | +79.82% |
| February, 2028 | $16.93 | $14.20 | $13.93 | +133.78% |
| March, 2028 | $16.34 | $16.86 | $16.94 | +125.75% |
| April, 2028 | $17.40 | $17.32 | $16.80 | +140.34% |
| May, 2028 | $16.94 | $17.18 | $17.29 | +133.96% |
| June, 2028 | $13.64 | $14.82 | $15.62 | +88.33% |
| July, 2028 | $13.69 | $14.05 | $13.54 | +89.11% |
| August, 2028 | $11.85 | $12.22 | $13.51 | +63.67% |
| September, 2028 | $7.9466 | $10.89 | $10.74 | +9.76% |
| October, 2028 | $10.00 | $10.25 | $9.4999 | +38.17% |
| November, 2028 | $10.60 | $9.9147 | $9.3765 | +46.43% |
| December, 2028 | $10.41 | $10.83 | $10.40 | +43.76% |
Recursion Pharmaceuticals Inc Stock (RXRX) Price Forecast for 2029
The 2029 price forecast for Recursion Pharmaceuticals Inc Stock (RXRX) is $7.1504 on average, with a high prediction of $11.81 and a low estimate of $2.4919. This represents an -1.24% decrease from the previous price of $7.24.
| Month | Average | Low | High | Change from today's price |
|---|---|---|---|---|
| January, 2029 | $11.56 | $10.93 | $11.35 | +59.62% |
| February, 2029 | $10.29 | $10.69 | $11.27 | +42.16% |
| March, 2029 | $10.41 | $10.65 | $10.21 | +43.77% |
| April, 2029 | $10.90 | $10.37 | $10.19 | +50.49% |
| May, 2029 | $11.48 | $10.99 | $10.68 | +58.62% |
| June, 2029 | $11.70 | $11.92 | $11.81 | +61.61% |
| July, 2029 | $8.3272 | $8.2105 | $10.29 | +15.02% |
| August, 2029 | $9.1554 | $7.5204 | $8.4554 | +26.46% |
| September, 2029 | $1.4619 | $2.4919 | $1.2319 | -79.81% |
| October, 2029 | $6.3401 | $3.5036 | $5.8702 | -12.43% |
| November, 2029 | $6.6867 | $6.1418 | $5.82 | -7.64% |
| December, 2029 | $8.2033 | $6.9583 | $7.4533 | +13.30% |
Recursion Pharmaceuticals Inc Stock (RXRX) Price Forecast for 2030
Recursion Pharmaceuticals Inc Stock (RXRX) is expected to reach an average price of $10.49 in 2030, with a high forecast of $20.69 and a low forecast of $0.2957. This signifies an +44.91% surge from the last price of $7.24.
| Month | Average | Low | High | Change from today's price |
|---|---|---|---|---|
| January, 2030 | $6.5815 | $8.4165 | $8.5765 | -9.10% |
| February, 2030 | $5.598 | $6.198 | $6.2931 | -22.68% |
| March, 2030 | $0.8346 | $3.2629 | $3.1847 | -88.47% |
| April, 2030 | $2.9211 | $2.1462 | $1.5579 | -59.65% |
| May, 2030 | $1.6707 | $0.2957 | $3.9507 | -76.92% |
| June, 2030 | $0.8659 | $0.8326 | $1.949 | -88.04% |
| July, 2030 | $2.6941 | $1.3075 | $2.5441 | -62.79% |
| August, 2030 | $22.38 | $2.8674 | $19.50 | +209.08% |
| September, 2030 | $13.29 | $15.66 | $18.95 | +83.53% |
| October, 2030 | $22.05 | $17.65 | $17.37 | +204.62% |
| November, 2030 | $20.89 | $21.57 | $20.69 | +188.60% |
| December, 2030 | $20.34 | $20.97 | $19.89 | +181.00% |
3.95%
2.39%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):